Allogene Therapeutics, Inc. Stock

Market capitalization is the stock price multiplied by the number of shares issued.

Allogene Therapeutics, Inc.

Enterprise value (EV) is a measure of the value of a company regardless of its financing. It is calculated as follows:
EV = market capitalization - cash + debt.

Enterprise Value metric explained

Allogene Therapeutics, Inc.

The P/E ratio or price/earnings ratio TTM (Trailing Twelve Months) over the last 12 months describes the ratio of the stock price to earnings per share.

Allogene Therapeutics, Inc.

If you divide the enterprise value by the Free Cash Flow of the last 12 months, you obtain an important metric for assessing the valuation of companies - even if they are not yet generating profits.

Allogene Therapeutics, Inc.

The P/B ratio TTM (Trailing Twelve Months) over the last 12 months describes the ratio of the stock price to the book value per share.

Allogene Therapeutics, Inc.

Sales growth TTM (Trailing Twelve Months) compares the sales of the last 12 months with the sales of the previous 12 months.

Allogene Therapeutics, Inc.

Revenue TTM (Trailing Twelve Months) represents the sum of all revenues of a company for its products, services or other items within the last 12 months.

Allogene Therapeutics, Inc.

EBIT or the operating result represents the profit or loss after deducting direct costs (cost of sales), sales, marketing, administrative, research and development costs and depreciation and amortization.

Allogene Therapeutics, Inc.

Free Cash Flow TTM (Trailing Twelve Months) provides information on how much of the profit generated over the last 12 months remains in the company's coffers and is therefore available for profit distributions, share buybacks or debt repayment.

Allogene Therapeutics, Inc.

Cash is defined as cash and cash equivalents (i.e. cash items of very high value).

Allogene Therapeutics, Inc.

EPS TTM (Trailing Twelve Months) or earnings per share represents the profit per share over the last 12 months. The company's net profit is divided by the number of shares.

Allogene Therapeutics, Inc.

Price/earnings ratio based on the expected net earnings per share for the financial year ending at Dec 31 2025.

Allogene Therapeutics, Inc.

Ratio of market capitalization to sales on the basis of expected sales for the financial year ending at Dec 31 2025

Allogene Therapeutics, Inc.

Ratio of enterprise value to sales based on estimated sales for the financial year ending at Dec 31 2025

Allogene Therapeutics, Inc.